Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Viral hepatitis

HBV cure—can we pin our hopes on immunotherapy?

Nature Reviews Gastroenterology & Hepatology volume 12, pages 129–131 (2015)Cite this article

Subjects

Therapeutic vaccines are considered to be able to reverse the dysfunctional immune state of chronic hepatitis B and thus hold the promise for HBV cure. Martin et al. developed a novel adenovirus-based therapeutic vaccine TG1050 and demonstrated its induction of long-lasting antiviral CD8+ T-cell immunity in mouse models of HBV persistence.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Curing chronic hepatitis B.

References

  1. Su, T. H. & Kao, J. H. Improving clinical outcomes of chronic hepatitis B virus infection. Expert Rev. Gastroenterol. Hepatol. http://dx.doi.org/10.1586/17474124.2015.960398 (2014).

  2. Martin, P. et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut http://dx.doi.org/10.1136/gutjnl-2014-308041 (2014).

  3. Bertoletti, A. & Ferrari, C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61, 1754–1764 (2012).

    Article  CAS  PubMed  Google Scholar 

  4. Jenne, C. N. & Kubes, P. Immune surveillance by the liver. Nat. Immunol. 14, 996–1006 (2013).

    Article  CAS  PubMed  Google Scholar 

  5. Boni, C. et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 39, 595–605 (2003).

    Article  CAS  PubMed  Google Scholar 

  6. Ning, Q. et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J. Hepatol. 61, 777–784 (2014).

    Article  CAS  PubMed  Google Scholar 

  7. Michel, M. L., Deng, Q. & Mancini-Bourgine, M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J. Hepatol. 54, 1286–1296 (2011).

    Article  CAS  PubMed  Google Scholar 

  8. Maini, M. K. & Schurich, A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J. Hepatol. 52, 616–619 (2010).

    Article  CAS  PubMed  Google Scholar 

  9. Lucifora, J. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343, 1221–1228 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lin, S. R. et al. The CRISPR/Cas9 System facilitates clearance of the intrahepatic HBV templates in vivo. Mol. Ther. Nucleic Acids 3, e186 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei, 10002, Taiwan

    Hung-Chih Yang

  2. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei, 10002, Taiwan

    Jia-Horng Kao

Authors
  1. Hung-Chih Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jia-Horng Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jia-Horng Kao.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, HC., Kao, JH. HBV cure—can we pin our hopes on immunotherapy?. Nat Rev Gastroenterol Hepatol 12, 129–131 (2015). https://doi.org/10.1038/nrgastro.2015.8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2015.8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing